- A-804598
-
- $31.00
-
2026-07-14
- CAS:1125758-85-1
- Purity: 99.80%
- Supply Ability: 10g
- A 804598
-
- $1.00
-
2019-12-23
- CAS:1125758-85-1
- Min. Order: 1g
- Purity: 99.99%
- Supply Ability: 200kg
|
| | A 804598 Basic information |
| Product Name: | A 804598 | | Synonyms: | A 804598;N-Cyano-N′′-[(1S)-1-phenylethyl]-N′-5-quinolinyl-guanidine;1-cyano-2-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine;2-Cyano-1-[(1S)-1-phenylethyl]-3-(5-quinolinyl)guanidine;A-804598 （(A 804598;CS-2234;Guanidine, N-cyano-N''-[(1S)-1-phenylethyl]-N'-5-quinolinyl-;S-2-Cyano-1-(1-phenylethyl)-3-(quinolin-5-yl)guanidine | | CAS: | 1125758-85-1 | | MF: | C19H17N5 | | MW: | 315.37 | | EINECS: | | | Product Categories: | | | Mol File: | 1125758-85-1.mol |  |
| | A 804598 Chemical Properties |
| Boiling point | 498.0±47.0 °C(Predicted) | | density | 1.17±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,2-8°C | | solubility | DMSO: soluble10mg/mL, clear | | pka | 4.52±0.12(Predicted) | | form | powder | | color | white to beige | | InChI | 1S/C19H17N5/c1-14(15-7-3-2-4-8-15)23-19(22-13-20)24-18-11-5-10-17-16(18)9-6-12-21-17/h2-12,14H,1H3,(H2,22,23,24)/t14-/m0/s1 | | InChIKey | PQYCRDPLPKGSME-AWEZNQCLSA-N | | SMILES | N(c2c3c(nccc3)ccc2)\C(=N/[C@@H](C)c1ccccc1)\NC#N |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | A 804598 Usage And Synthesis |
| Uses | A 804598 is a P2X7 antagonist. | | Biological Activity | a 804598 is a potent and selective antagonist of p2x7 receptor with ic50 values of 8.9, 9.9 and 10.9 nm for mouse, rat and human p2x7 receptors, respectively [1].p2x purinoceptor 7 (p2x7 receptor) is a purinoceptor and is activated by high concentrations of atp. p2x7 receptor plays an important role in atp-mediated cell death, inflammation and regulation of receptor trafficking.a 804598 is a potent and selective p2x7 receptor antagonist. in differentiated thp-1 cells that expressed human p2x7 receptors, a 804598 inhibited bzatp stimulated yo-pro uptake and release of il-1β. in 1321n1 cells expressed recombinant rat p2x7 receptor, a 804598 showed high affinity with kd = 2.4 nm [1]. a 804598 inhibited bz-atp stimulated calcium influx with ic50 value of 28.71 nm in a concentration-dependent way. a-804598 was a potent p2x7 receptor antagonist with ki value of 7.51 nm [2].in adult male rats, footshock increased the mrna levels of cd14 and il-1β in the paraventricular nucleus. while a-804598 (25 mg/kg) partially inhibited these effects [3]. | | in vivo | A chroni treatment with A-804598 (intraperitoneal injection; 30 mg/kg; five times a week) decreases the expression of LC3B-II and SQSTM1/p62 in lumbar spinal cord at end stage of disease[3]. | Animal Model: | Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice [3] | | Dosage: | 30 mg/kg | | Administration: | Intraperitoneal injection; five times a week | | Result: | Decreased SQSTM1/p62 expression. |
| | IC 50 | P2X7 Receptor | | storage | Store at -20°C | | references | [1]. donnelly-roberts dl, namovic mt, surber b, et al. [3h]a-804598 ([3h]2-cyano-1-[(1s)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for p2x7 receptors. neuropharmacology, 2009, 56(1): 223-229.
[2]. able sl, fish rl, bye h, et al. receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant p2x7 antagonists in the rat. br j pharmacol. 2011, 162(2): 405-414.
[3]. catanzaro jm1, hueston cm, deak mm, et al. the impact of the p2x7 receptor antagonist a-804598 on neuroimmune and behavioral consequences of stress. behav pharmacol, 2014, 25(5-6): 582-598. |
| | A 804598 Preparation Products And Raw materials |
|